Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation

Published: 04 March 2021

Views:
30451
Likes:
7

Views:
30451
Likes:
7
Share:

Now Playing
Part 5
Ken Okumura
Ken Okumura

Up Next

14m 39s

Part 6 Panel Discussion Moderated by John Eikelboom

13m 16s

Part 1 Jan Steffel John Eikelboom, Ken Okumura, Jan Steffel, Stefan H Hohnloser

14m 25s

Part 2 Stefan H Hohnloser Stefan H Hohnloser

13m 24s

Part 3 Jan Steffel Jan Steffel

10m 29s

Part 4 Panel discussion moderated by John Eikelboom John Eikelboom

Average (ratings)

No ratings

Your rating

Overview

In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.

Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.

This activity has been supported via an educational grant from Boehringer Ingelheim

Learning Objectives

Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
Interpret safety and cardiovascular data from RCTs in the context of real-world experience
Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC

Target Audience

Cardiologists
Interventional Cardiologists

More from this programme

Part 1

When to Initiate a NOAC and Patient Suitability (data presentation)

An overview of current guidelines

1 session
Jan Steffel	Watch now

Part 2

Overview of Safety and Cardiovascular Data

a. Safety and cardiovascular data from RCTs b. Real-world and meta-analyses

1 session
Stefan H Hohnloser	Watch now

Part 3

Dealing with Complications:

Major bleeding events and reversal

1 session
Jan Steffel	Watch now

Part 4

Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)

Panel recommendations of NOAC choice according to different patient populations

1 session
Panel discussion moderated by John Eikelboom	Watch now

Part 5

NOAC Use with Ablation and Intervention

a. Guideline recommendations and current trends b. Use of NOACs with ablation in Japan: clinical data

1 session
Ken Okumura	Watch now

Part 6

Discussion on the Current Use of NOACs in Japan

a. Use in elderly/very old pts b. Under-dosing of NOACs c. Current unmet needs

1 session
Panel Discussion Moderated by John Eikelboom	Watch now

Faculty Biographies

Ken Okumura

Ken Okumura

Prof. Ken Okumura served as a Professor of Medicine at Hirosaki University School of Medicine from 1996 to 2016. He also served as a President of the Japanese Heart Rhythm Society (JHRS) from 2012 to 2016. He is now working at Saiseikai Kumamoto Hospital Cardiovascular Center, Japan, while providing the latest interventional treatments for cardiac arrhythmias especially catheter ablation of AF. His main interests include pharmacological and non-pharmacological treatments of cardiac arrhythmias, catheter ablation of persistent AF, and oral anticoagulant therapy for stroke prevention in AF especially in the elderly AF patients.

View full profile